Etienne Marc Sokal
Fondatore presso PROMETHERA Biosciences SA
Posizioni attive di Etienne Marc Sokal
Società | Posizione | Inizio | Fine |
---|---|---|---|
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Presidente | 01/09/2020 | - |
Fondatore | 12/02/2009 | - | |
Direttore/Membro del Consiglio | 12/02/2009 | 01/09/2020 | |
Direttore Tecnico/Scientifico/R&S | 03/11/2009 | 21/02/2020 | |
Université Catholique de Louvain | Corporate Officer/Principal | - | - |
Cliniques Universitaires Saint-Luc
Cliniques Universitaires Saint-Luc Hospital/Nursing ManagementHealth Services Cliniques Universitaires Saint-Luc operates as a hospital which provides reference care and treats serious, rare or complex diseases of patients. The company was founded on August 23, 1976 and is headquartered in Brussels, Belgium. | Corporate Officer/Principal | - | - |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/04/2021 | - |
Amministratore Delegato | 01/04/2021 | - | |
Fondatore | - | - |
Storia della carriera di Etienne Marc Sokal
Formazione di Etienne Marc Sokal
Université Catholique de Louvain | Doctorate Degree |
Statistiche
Distribuzione geografica
Belgio | 5 |
Posizioni
Director/Board Member | 2 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
Cliniques Universitaires Saint-Luc
Cliniques Universitaires Saint-Luc Hospital/Nursing ManagementHealth Services Cliniques Universitaires Saint-Luc operates as a hospital which provides reference care and treats serious, rare or complex diseases of patients. The company was founded on August 23, 1976 and is headquartered in Brussels, Belgium. | Health Services |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Etienne Marc Sokal
- Esperienza